Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Abstract Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICI...

ver descrição completa

Detalhes bibliográficos
Main Authors: Adam Lauko, Rupesh Kotecha, Addison Barnett, Hong Li, Vineeth Tatineni, Assad Ali, Pradnya Patil, Alireza M. Mohammadi, Samuel T. Chao, Erin S. Murphy, Lilyana Angelov, John H. Suh, Gene H. Barnett, Nathan A. Pennell, Manmeet S. Ahluwalia
Formato: Artigo
Idioma:English
Publicado em: Nature Portfolio 2021-09-01
Colecção:Scientific Reports
Acesso em linha:https://doi.org/10.1038/s41598-021-97566-z

Internet

https://doi.org/10.1038/s41598-021-97566-z

Registos relacionados